Loading...
NextCure, Inc.
NXTC•NASDAQ
Healthcare
Biotechnology
$0.50
$-0.18(-26.27%)
NextCure, Inc. (NXTC) Financial Performance & Statements
Review NextCure, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
0.00%
Operating Income Growth
11.66%
↑ 11.66%
Net Income Growth
11.27%
↑ 11.27%
Operating Cash Flow Growth
22.97%
↑ 22.97%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-70.16%
↓ 70.16%
ROIC
-86.43%
↓ 86.43%
NextCure, Inc. (NXTC) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for NextCure, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $701000.00 | $940000.00 |
| Gross Profit | $0.00 | $0.00 | -$701000.00 | -$940000.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $8.90M | $8.77M | $12.42M | $11.40M |
| SG&A Expenses | $3.55M | $3.73M | $3.38M | $3.42M |
| Operating Expenses | $12.46M | $12.49M | $15.79M | $14.82M |
| Total Costs & Expenses | $12.46M | $12.49M | $16.49M | $15.76M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $674000.00 | $700000.00 | $701000.00 | $940000.00 |
| EBITDA | -$11.78M | -$11.79M | -$15.79M | -$14.97M |
| EBITDA Ratio | ||||
| Operating Income | -$12.46M | -$12.49M | -$16.49M | -$15.76M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $852000.00 | $955000.00 | $1.09M | -$1.34M |
| Income Before Tax | -$11.60M | -$11.54M | -$15.40M | -$17.11M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $896724.00 |
| Net Income | -$11.60M | -$11.54M | -$15.40M | -$17.11M |
| Net Income Ratio | ||||
| EPS | -$0.41 | -$0.41 | -$0.55 | -$0.61 |
| Diluted EPS | -$0.41 | -$0.41 | -$0.55 | -$0.61 |
| Weighted Avg Shares Outstanding | $27.98M | $27.98M | $27.97M | $27.90M |
| Weighted Avg Shares Outstanding (Diluted) | $27.98M | $27.98M | $27.97M | $27.90M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan